Retroviral Coexpression of a Multidrug Resistance Gene (MDR1) and Human α-Galactosidase A for Gene Therapy of Fabry Disease

Yoshikazu Sugimoto, Ivan Aksentijevich, Gary J. Murray, Roscoe O. Brady, Ira Pastan, Michael M. Gottesman

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Human α-galactosidase A (α-Gal A; EC. 3.2.1.22) is a lysosomal exoglycosidase encoded by a gene on Xq22. Deficiencies of this enzyme result in Fabry disease, an X-chromosome-linked recessive disorder that leads to premature death in affected males. For treatment of genetic diseases, we have developed a retroviral vector system, pSXLC/pHa, that enables coexpression of drug-selectable markers with a second nonselectable gene as part of a bicistronic message using the promoter from the Harvey murine sarcoma virus and an internal ribosomal entry site (IRES) from encephalomyocarditis virus. Retroviral vectors based on this system that carry the human α-Gal A cDNA either upstream (pHa-αGal-IRES-MDR) or downstream (pHa-MDR-IRES-αGal) from the IRES relative to the drug-selectable MDR1 (P-glycoprotein) cDNA were constructed. Each of eight independent vincristine-resistant, pHa-αGal-IRES-MDR-transfected clones and all four vincristine-resistant, pHa-αGal-IRES-MDR retrovirus-transduced clones showed significantly higher activity of α-Gal A than the parental cells. More than 50% of the vincristine-resistant, pHa-MDR-IRES-αGal-transfected clones and all four vincristine-resistant, pHa-MDR-IRES-αGal retrovirus-transduced clones showed significantly higher activity of α-Gal A than the parental cells. In these bicistronic vectors, the cDNA whose translation was cap-dependent (upstream) was expressed at higher levels than when the same cDNA was translated in an IRES-dependent manner (downstream). These vectors may prove useful in the gene therapy of Fabry disease.

Original languageEnglish
Pages (from-to)905-915
Number of pages11
JournalHuman Gene Therapy
Volume6
Issue number7
DOIs
Publication statusPublished - 1995 Jul 1
Externally publishedYes

Fingerprint

Galactosidases
MDR Genes
Fabry Disease
Vincristine
Genetic Therapy
Complementary DNA
Clone Cells
Retroviridae
Harvey murine sarcoma virus
Encephalomyocarditis virus
Inborn Genetic Diseases
Premature Mortality
Glycoside Hydrolases
X Chromosome
P-Glycoprotein
Pharmaceutical Preparations
Genes
Enzymes

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Retroviral Coexpression of a Multidrug Resistance Gene (MDR1) and Human α-Galactosidase A for Gene Therapy of Fabry Disease. / Sugimoto, Yoshikazu; Aksentijevich, Ivan; Murray, Gary J.; Brady, Roscoe O.; Pastan, Ira; Gottesman, Michael M.

In: Human Gene Therapy, Vol. 6, No. 7, 01.07.1995, p. 905-915.

Research output: Contribution to journalArticle

Sugimoto, Yoshikazu ; Aksentijevich, Ivan ; Murray, Gary J. ; Brady, Roscoe O. ; Pastan, Ira ; Gottesman, Michael M. / Retroviral Coexpression of a Multidrug Resistance Gene (MDR1) and Human α-Galactosidase A for Gene Therapy of Fabry Disease. In: Human Gene Therapy. 1995 ; Vol. 6, No. 7. pp. 905-915.
@article{a716930d792b4384a16a0440a8024788,
title = "Retroviral Coexpression of a Multidrug Resistance Gene (MDR1) and Human α-Galactosidase A for Gene Therapy of Fabry Disease",
abstract = "Human α-galactosidase A (α-Gal A; EC. 3.2.1.22) is a lysosomal exoglycosidase encoded by a gene on Xq22. Deficiencies of this enzyme result in Fabry disease, an X-chromosome-linked recessive disorder that leads to premature death in affected males. For treatment of genetic diseases, we have developed a retroviral vector system, pSXLC/pHa, that enables coexpression of drug-selectable markers with a second nonselectable gene as part of a bicistronic message using the promoter from the Harvey murine sarcoma virus and an internal ribosomal entry site (IRES) from encephalomyocarditis virus. Retroviral vectors based on this system that carry the human α-Gal A cDNA either upstream (pHa-αGal-IRES-MDR) or downstream (pHa-MDR-IRES-αGal) from the IRES relative to the drug-selectable MDR1 (P-glycoprotein) cDNA were constructed. Each of eight independent vincristine-resistant, pHa-αGal-IRES-MDR-transfected clones and all four vincristine-resistant, pHa-αGal-IRES-MDR retrovirus-transduced clones showed significantly higher activity of α-Gal A than the parental cells. More than 50{\%} of the vincristine-resistant, pHa-MDR-IRES-αGal-transfected clones and all four vincristine-resistant, pHa-MDR-IRES-αGal retrovirus-transduced clones showed significantly higher activity of α-Gal A than the parental cells. In these bicistronic vectors, the cDNA whose translation was cap-dependent (upstream) was expressed at higher levels than when the same cDNA was translated in an IRES-dependent manner (downstream). These vectors may prove useful in the gene therapy of Fabry disease.",
author = "Yoshikazu Sugimoto and Ivan Aksentijevich and Murray, {Gary J.} and Brady, {Roscoe O.} and Ira Pastan and Gottesman, {Michael M.}",
year = "1995",
month = "7",
day = "1",
doi = "10.1089/hum.1995.6.7-905",
language = "English",
volume = "6",
pages = "905--915",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "7",

}

TY - JOUR

T1 - Retroviral Coexpression of a Multidrug Resistance Gene (MDR1) and Human α-Galactosidase A for Gene Therapy of Fabry Disease

AU - Sugimoto, Yoshikazu

AU - Aksentijevich, Ivan

AU - Murray, Gary J.

AU - Brady, Roscoe O.

AU - Pastan, Ira

AU - Gottesman, Michael M.

PY - 1995/7/1

Y1 - 1995/7/1

N2 - Human α-galactosidase A (α-Gal A; EC. 3.2.1.22) is a lysosomal exoglycosidase encoded by a gene on Xq22. Deficiencies of this enzyme result in Fabry disease, an X-chromosome-linked recessive disorder that leads to premature death in affected males. For treatment of genetic diseases, we have developed a retroviral vector system, pSXLC/pHa, that enables coexpression of drug-selectable markers with a second nonselectable gene as part of a bicistronic message using the promoter from the Harvey murine sarcoma virus and an internal ribosomal entry site (IRES) from encephalomyocarditis virus. Retroviral vectors based on this system that carry the human α-Gal A cDNA either upstream (pHa-αGal-IRES-MDR) or downstream (pHa-MDR-IRES-αGal) from the IRES relative to the drug-selectable MDR1 (P-glycoprotein) cDNA were constructed. Each of eight independent vincristine-resistant, pHa-αGal-IRES-MDR-transfected clones and all four vincristine-resistant, pHa-αGal-IRES-MDR retrovirus-transduced clones showed significantly higher activity of α-Gal A than the parental cells. More than 50% of the vincristine-resistant, pHa-MDR-IRES-αGal-transfected clones and all four vincristine-resistant, pHa-MDR-IRES-αGal retrovirus-transduced clones showed significantly higher activity of α-Gal A than the parental cells. In these bicistronic vectors, the cDNA whose translation was cap-dependent (upstream) was expressed at higher levels than when the same cDNA was translated in an IRES-dependent manner (downstream). These vectors may prove useful in the gene therapy of Fabry disease.

AB - Human α-galactosidase A (α-Gal A; EC. 3.2.1.22) is a lysosomal exoglycosidase encoded by a gene on Xq22. Deficiencies of this enzyme result in Fabry disease, an X-chromosome-linked recessive disorder that leads to premature death in affected males. For treatment of genetic diseases, we have developed a retroviral vector system, pSXLC/pHa, that enables coexpression of drug-selectable markers with a second nonselectable gene as part of a bicistronic message using the promoter from the Harvey murine sarcoma virus and an internal ribosomal entry site (IRES) from encephalomyocarditis virus. Retroviral vectors based on this system that carry the human α-Gal A cDNA either upstream (pHa-αGal-IRES-MDR) or downstream (pHa-MDR-IRES-αGal) from the IRES relative to the drug-selectable MDR1 (P-glycoprotein) cDNA were constructed. Each of eight independent vincristine-resistant, pHa-αGal-IRES-MDR-transfected clones and all four vincristine-resistant, pHa-αGal-IRES-MDR retrovirus-transduced clones showed significantly higher activity of α-Gal A than the parental cells. More than 50% of the vincristine-resistant, pHa-MDR-IRES-αGal-transfected clones and all four vincristine-resistant, pHa-MDR-IRES-αGal retrovirus-transduced clones showed significantly higher activity of α-Gal A than the parental cells. In these bicistronic vectors, the cDNA whose translation was cap-dependent (upstream) was expressed at higher levels than when the same cDNA was translated in an IRES-dependent manner (downstream). These vectors may prove useful in the gene therapy of Fabry disease.

UR - http://www.scopus.com/inward/record.url?scp=0028821345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028821345&partnerID=8YFLogxK

U2 - 10.1089/hum.1995.6.7-905

DO - 10.1089/hum.1995.6.7-905

M3 - Article

C2 - 7578409

AN - SCOPUS:0028821345

VL - 6

SP - 905

EP - 915

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 7

ER -